Owlstone Medical wins Life Science Innovation award

Owlstone Medical headed off fierce competition to take the Business Weekly 2016 AstraZeneca/MedImmune Life Science Innovation Award.

Published on: 30 Mar 2016

Owlstone Medical headed off fierce competition to take the Business Weekly 2016 AstraZeneca/MedImmune Life Science Innovation Award.

Jane Osbourn of MedImmune, said: “Owlstone’s newly-formed medical division has invented a breath test to provide much earlier diagnosis of cancer, asthma and other diseases and conditions. We were impressed by the potential of the technology to save the NHS millions, slash hospital admissions and – most importantly because of swifter diagnosis – to save lives.”

PDF article from Business Weekly

Web article on businessweekly.co.uk

Owlstone receive Life Science Innovation Award
Owlstone founders Andrew Koehl (left), David Ruiz-Alonso (second left) and Billy Boyle (centre) receive the Life Science Innovation award by guest speaker Warren East (CEO of Rolls-Royce) and Jane Osbourn of MedImmune.

About Owlstone Medical

Owlstone Medical has developed a breathalyzer for disease.

Our Vision: Owlstone Medical will become the global leader in non-invasive diagnostics for cancer, infectious disease and inflammatory disease.

Our Mission: Save 100,000 lives and save $1.5B in health care costs by 2020. www.owlstonemedical.com #save100klives

Owlstone newsletter CTA

Talk to us about your biomarker research and how Breath Biopsy could help.

Contact Us